Form 4: DexCom Director Transfers Shares to Revocable Trust

Director Richard Alexander Collins transferred 5,074 shares of DexCom common stock into his revocable trust.

Summary

• Director Richard Alexander Collins executed a transfer of 5,074 shares of DexCom common stock on May 8, 2026.
• The transaction involved moving shares from direct ownership to the Richard A. Collins Revocable Trust.
• The transfer was executed as a gift (Code G) with a price of $0, reflecting a change in ownership structure rather than a market sale.
• Following the transaction, the reporting person holds 40,162 shares indirectly through the trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is purely an administrative change in ownership structure for estate planning purposes.

Positives

• The transaction represents a consolidation of holdings into a trust, which is a standard estate planning practice.
• There was no divestment of equity; the director maintains beneficial ownership of the shares.

Negatives

• None identified; this is a routine administrative filing regarding ownership structure.

Risks

• None identified; this filing pertains to internal ownership changes.

Future Outlook

No forward-looking guidance or operational outlook provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings regarding trust transfers are common among corporate directors and do not typically signal changes in sentiment regarding company performance or market outlook.

Comparison to Industry Standards

• The transfer of shares to a revocable trust is a standard governance and estate planning procedure consistent with practices at other large-cap medical device companies.

Stakeholder Impact

• No material impact on shareholders, employees, or customers as the director's total beneficial ownership remains unchanged.

Next Steps

• None indicated.

Key Dates

Keywords

DexCom, DXCM, Form 4, Insider Ownership, Director Transaction, Estate Planning